Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 8, 2023

Research Progress of Immune Checkpoint Inhibitors in Melanoma

Download as PDF

DOI: 10.23977/medsc.2023.040811 | Downloads: 10 | Views: 274

Author(s)

Xinyu Chang 1, Liwen Wang 2

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
2 Department of Dermatology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712000, China

Corresponding Author

Liwen Wang

ABSTRACT

Melanoma, also known as malignant melanoma, is a malignant tumor originating from melanocytes that is highly malignant, aggressive, and has a poor prognosis. Although melanoma accounts for about 10% of skin cancers, melanoma is the leading cause of death from skin cancers. Thus, it is essential to study the treatment of melanoma. Immunotherapy has produced durable clinical responses with long-term remissions in melanoma. In this article, we present a review of immune checkpoint inhibitors in melanoma treatment, and will introduce CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors.

KEYWORDS

Melanoma; immunotherapy; immune checkpoint; CTLA-4; PD-1; PD-L1

CITE THIS PAPER

Xinyu Chang, Liwen Wang, Research Progress of Immune Checkpoint Inhibitors in Melanoma. MEDS Clinical Medicine (2023) Vol. 4: 73-79. DOI: http://dx.doi.org/10.23977/medsc.2023.040811.

REFERENCES

[1] Davis Lauren E, Shalin Sara C, Tackett Alan J, et al. Current state of melanoma diagnosis and treatment [J]. Cancer biology & therapy, 2019, 20(11):1366-1379.
[2] Schadendorf Dirk, Hodi F Stephen, Robert Caroline, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma [J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2015, 33(17):1889-1894.
[3] C. Lebbé, J.S. Weber, M. Maio, et al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies [J]. Annals of Oncology, 2014, 25(11):2277-2284.
[4] Meyers D E, Banerji S. Biomarkers of immune checkpoint inhibitor efficacy in cancer [J]. Current oncology (Toronto, Ont.), 2020, 27(2):S106-S114.
[5] Li Bin, Chan Ho Lam, Chen Pingping, et al. Immune Checkpoint Inhibitors: Basics and Challenges [J]. Current medicinal chemistry, 2019, 26(17):3009-3025.
[6] Lv Mengze, Chen Meixia, Zhang Rui, et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy [J]. Cell research, 2020, 30(11):966-979.
[7] Zhao Yujie, Liu Xu, Liu Xinyu, et al. Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer [J]. Frontiers in Immunology, 2022, 13:955920-955920.
[8] Priyanka Khanna, Normand Blais, Pierre-Olivier Gaudreau, et al. Immunotherapy Comes of Age in Lung Cancer [J]. Clinical Lung Cancer, 2016, 18(1):13-22.
[9] Zhang Hao, Dai Ziyu, Wu Wantao, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer [J]. Journal of Experimental & Clinical Cancer Research, 2021, 40(1):184-184.
[10] Zhao Yinghao, Yang Wei, Huang Yuanyuan, et al. Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy [J]. Cellular Physiology and Biochemistry, 2018, 47(2):721-734.
[11] Rowshanravan Behzad, Halliday Neil, Sansom David M, et al. CTLA-4: a moving target in immunotherapy [J]. Blood, 2018, 131(1):58-67.
[12] Sharpe Arlene H, Abbas Abul K. T-cell costimulation--biology, therapeutic potential, and challenges [J]. The New England journal of medicine, 2006, 355(10):973-975.
[13] Carreno B M, Bennett F, Chau T A, et al. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression [J]. Journal of immunology (Baltimore, Md.: 1950), 2000, 165(3):1352-1356.
[14] Wojtukiewicz Marek Z, Rek Magdalena M, Karpowicz Kamil, et al. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners [J]. Cancer metastasis reviews, 2021, 40(3):1-34.
[15] Dalle Stéphane, Mortier Laurent, Corrie Pippa, et al. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study [J]. BMC Cancer, 2021, 21(1):642-642.
[16] Larkin James, Chiarion-Sileni Vanna, Gonzalez Rene, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma [J]. The New England journal of medicine, 2019, 381(16):1535-1546.
[17] Ribas Antoni, Kefford Richard, Marshall Margaret A, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma [J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, 31(5):616-622.
[18] Bajor David L, Mick Rosemarie, Riese Matthew J, et al. Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma [J]. Oncoimmunology, 2018, 7(10):e1468956.
[19] Xuewu Zhang, Jean-Claude D. Schwartz, Xiaoling Guo, et al. Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1 [J]. Immunity, 2004, 20(3):337-347.
[20] Han Jiaqian, Xu Xiaobo, Liu Zi, et al. Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma [J]. International Immunopharmacology, 2020, 88:106971.
[21] Zhou Lijuan, Wen Liang, Sheng Youyu, et al. The PD-1/PD-L1 pathway in murine hair cycle transition: a potential anagen phase regulator[J]. Archives of Dermatological Research, 2021, 313(9):1-8.
[22] Hosseinzadeh Ramin, Feizisani Fahimeh, Shomali Navid, et al. PD-1/PD-L1 Blockade: Prospectives for immunotherapy in Cancer and Autoimmunity [J]. IUBMB life, 2021, 73(11):1293-1306.
[23] Brahmer Julie R, Drake Charles G, Wollner Ira, et al. Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 41(4):715-723.
[24] Larkin James, Minor David, D'Angelo Sandra, et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial [J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 36(4):383-390.
[25] Yamazaki Naoya, Takenouchi Tatsuya, Nakamura Yasuhiro, et al. Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study) [J]. Japanese journal of clinical oncology, 2021, 51(8):1232-1241.
[26] Barone Amy, Hazarika Maitreyee, Theoret Marc R, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma [J]. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, 23(19):5661-5665.
[27] Bottomley Andrew, Coens Corneel, Mierzynska Justyna, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial [J]. The Lancet Oncology, 2021, 22(5):655-664.
[28] Shiravand Yavar, Khodadadi Faezeh, Kashani Seyyed Mohammad Amin, et al. Immune Checkpoint Inhibitors in Cancer Therapy [J]. Current Oncology, 2022, 29(5):3044-3060.
[29] Ribas Antoni, Algazi Alain, Ascierto Paolo A, et al. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma [J]. Nature Communications, 2020, 11(1):6262-6262.
[30] Keilholz Ulrich, Mehnert Janice M, Bauer Sebastian, et al. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial [J]. Journal for immunotherapy of cancer, 2019, 7(1):12.
[31] Bagchi Sreya, Yuan Robert, Engleman Edgar G, et al. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance [J]. Annual review of pathology, 2020, 16: 223-249.
[32] Gomes Nuno, Sibaud Vincent, Azevedo Filomena, et al. Cutaneous Toxicity of Immune Checkpoint Inhibitors: A Narrative Review [J]. Acta medica portuguesa, 2020, 33(5):335-343.
[33] Horvat Troy Z, Adel Nelly G, Dang Thu-Oanh, et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center [J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2015, 33(28):3193-3198.
[34] Postow Michael A. Managing immune checkpoint-blocking antibody side effects [J]. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting, 2015:76-83.
[35] Wang Quanqiu, Xu Rong. Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis.[J]. JAMIA open, 2019, 2(1):173-178.
[36] Gide Tuba N, Pires da Silva Inês, Quek Camelia, et al. Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets [J]. Cancers, 2021, 13(13):3186-3186.
[37] Gide Tuba N, Wilmott James S, Scolyer Richard A, et al. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma [J]. Clinical cancer research: an official journal of the American Association for Cancer Research, 2018, 24(6):1260-1270.
[38] Kluger Harriet M, Tawbi Hussein A, Ascierto Maria L, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce [J]. Journal for immunotherapy of cancer, 2020, 8(1):e000398.
[39] Maria Letizia Motti, Michele Minopoli, Gioconda Di Carluccio, et al. MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors [J]. International Journal of Molecular Sciences, 2020, 21(12):4544.
[40] Veronica Huber, Viviana Vallacchi, Viktor Fleming, et al. Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma [J]. Journal of Clinical Investigation, 2018, 128(12):5505-5516.
[41] Cortez Maria Angelica, Anfossi Simone, Ramapriyan Rishab, et al. Role of miRNAs in immune responses and immunotherapy in cancer [J]. Genes, chromosomes & cancer, 2019, 58(4):244-253.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4554
Visits: 197117

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.